Companies › Kriya Therapeutics
6 active drug programs in 7 registered trials: 7 Phase 1; Metabolic and endocrine, Ophthalmology, Neurology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VV-14295 (KRIYA-825) Adeno-associated virus (AAV) vector delivering a soluble fms-like tyrosine kinase-1 (sFlt- | CFB | Phase 1 | Geographic Atrophy Secondary to Age-related Macular Degeneration | Dec 2027 |
| VV-14303 Gene therapy vector | – | Phase 1 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | Jul 2028 |
| VV-14305 (KRIYA-586) Gene therapy for thyroid eye disease | – | Phase 1 | Thyroid Eye Disease (TED) | Aug 2028 |
| VV-14300 Gene therapy designed to help remove excess sugar from blood | – | Phase 1 | Type 1 Diabetes Mellitus | Nov 2028 |
| RP-008 (KRIYA-748) Gene therapy | – | Phase 1 | Trigeminal Neuralgia | Feb 2029 |
| VV-14299 Gene therapy designed to work with VV-14300 to help remove excess sugar from blood | – | Phase 1 | Type 1 Diabetes Mellitus | Jul 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06765980 | VV-14295 (KRIYA-825) | Phase 1 | Geographic Atrophy Secondary to Age-related Macular Degeneration | Ophthalmology | Dec 2027 |
| NCT07732400 | VV-14303 | Phase 1 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | Metabolic and endocrine | Jul 2028 |
| NCT07404111 | VV-14305 (KRIYA-586) | Phase 1 | Thyroid Eye Disease (TED) | Ophthalmology | Aug 2028 |
| NCT07831798 | VV-14300 | Phase 1 | Type 1 Diabetes Mellitus | Metabolic and endocrine | Nov 2028 |
| NCT07596485 | RP-008 (KRIYA-748) | Phase 1 | Trigeminal Neuralgia | Neurology | Feb 2029 |
| NCT07829302 | VV-14300 | Phase 1 | Type 1 Diabetes Mellitus | Metabolic and endocrine | Jul 2029 |
| NCT07829302 | VV-14299 | Phase 1 | Type 1 Diabetes Mellitus | Metabolic and endocrine | Jul 2029 |
Regeneron Pharmaceuticals Novartis Suzhou Sanegene Bio Nanjing Chia-tai Tianqing Pharmaceutical
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.